CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir. Phase 3 data from the PrTK03 trial (NCT01436968) were recently presented at the ...

Joy Maulik, CRNP, speaks with J. Brandon Arruda, APRN, AGNP-C, CUNP, about the evolving role of advanced practice providers in urology. In this episode of The Expert Approach: Conversations in ...

Mitomycin for intravesical solution shows robust efficacy in treating recurrent LG-IR-NMIBC, with high complete response rates across multiple clinical trials. The treatment offers a non-surgical ...

The Expert APProach: Conversations in Uro-Oncology, hosted by Joy Maulik, CRNP, is the latest multimedia program from Urology Times. In this debut episode of The Expert APProach: Conversations in ...

Flibanserin received FDA priority review for expanded use in postmenopausal women with hypoactive sexual desire disorder, building on its 2015 approval for premenopausal women. Gepotidacin was ...

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Melvin L.K. Chua, FRCR, PhD, FASCO, highlights data validating the performance of the ArteraAI Prostate test in an Asian cohort of patients with prostate cancer. Data presented at the American Society ...

Johnson & Johnson's gemcitabine intravesical system approved for BCG-unresponsive NMIBC, showing an 82% complete response rate in the SunRISe-1 trial. Medtronic's Altaviva device approved for urge ...

The FloStent device showed promise in enabling catheter-free voiding in BPH-related urinary retention, with improved symptom scores and quality of life. HoLEP is gaining popularity for its ...

Zenflow's Spring Scope, a single-use cystoscope, received FDA 510(k) clearance, featuring a 12 French working channel for improved visualization. The Zenflow Spring System showed a 46% improvement in ...

PAM50 gene expression signature identifies prostate cancer patients who benefit from hormone therapy post-radical prostatectomy. Luminal B tumors showed significant improvement in bPFS and MFS with ...

Combining BCG with ICIs targets the PD-1/PD-L1 pathway to overcome BCG resistance in NMIBC. The CREST trial showed improved event-free survival with BCG plus sasanlimab compared to BCG alone. Future ...